February 4, 2025Open Access

Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study provides updated rank-order efficacy of MASH pharmacological therapies for fibrosis regression and MASH resolution. These data are helpful to inform practice and clinical trial design.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Souza et al. (Tue,) studied this question.

synapsesocial.com/papers/69d7262c424c1fc5df563be9 https://doi.org/https://doi.org/10.1097/hep.0000000000001254

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH2021 · 89 citations
2RoB 2: a revised tool for assessing risk of bias in randomised trials2019 · 31,116 citations
3Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study2019 · 211 citations
4The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review2023 · 3,019 citations
5Liver biopsy evaluation in MASH drug development: Think thrice, act wise2024 · 31 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo